Novo Nordisk (CPSE:NOVO B) Reaches LX9851 Obesity Drug Milestone
Bailey Pemberton
Mon, August 24, 2026 at 10:39 PM GMT+5:30
3 min read
- NVO
+2.56% - LXRX
+0.65% - NVO
+2.56%
Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide
Novo Nordisk (CPSE:NOVO B) and Lexicon Pharmaceuticals reached a key milestone in the development of first in class oral obesity drug LX9851
Lexicon received a milestone payment from Novo Nordisk tied to clinical progress for LX9851 in obesity and metabolic disorders
The advancement of LX9851 adds a new mechanism of action to Novo Nordisk’s obesity pipeline alongside its existing treatments
The update underscores ongoing efforts to address obesity as a major global health challenge with next generation therapies
For a wider view on how healthcare companies are using new tools and data driven approaches, explore 131 healthcare AI stocks
Novo Nordisk, a pharmaceuticals company with a DKK1.3 trillion market cap, focuses on researching, developing, manufacturing, and distributing treatments in areas such as obesity and metabolic disorders, so LX9851 fits directly into its core therapeutic focus. For readers tracking how large drug makers expand in obesity care, this collaboration with Lexicon Pharmaceuticals highlights how Novo Nordisk is using external partnerships alongside internal research
We’ve flagged 2 risks for Novo Nordisk. See which could impact your investment
How does LX9851 fit into Novo Nordisk’s obesity strategy?
LX9851 adds an oral, non incretin mechanism alongside Novo Nordisk’s existing GLP 1 based obesity and diabetes treatments. For investors, it broadens the toolkit in a market where less than 1% of people with obesity are treated with branded medications, according to the Narrative data. This supports Novo Nordisk’s push to serve a wider share of that untreated population
Does this LX9851 progress change the Novo Nordisk Narrative?
The progress on LX9851 leans into the Narrative theme that future returns will rely heavily on obesity pills while the company manages pipeline setbacks. It supports the catalyst around expanding metabolic disease treatments and product formats, which could help offset risks such as pricing pressure and patent expiry highlighted in the Narrative
If we take a look at the community Narrative for Novo Nordisk, we can see how this news fits into the bigger investment story
What should investors watch next to judge if LX9851 is on track?
The clearest early signal will be how LX9851 moves through later stage trials, particularly whether Novo Nordisk advances it into Phase 2 and outlines a timetable for obesity and metabolic disorder indications. Any future updates on dosing, tolerability and planned trial size will help investors judge how central LX9851 could become in the obesity portfolio
